Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.

[1]  U. Kralisz,et al.  Activation of Blood Platelets after Percutaneous Transluminal Coronary Angioplasty and Coronary Artery Bypass Graft Surgery , 2000, Journal of Thrombosis and Thrombolysis.

[2]  Eric J. Topol,et al.  Scientific and therapeutic advances in antiplatelet therapy , 2003, Nature Reviews Drug Discovery.

[3]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[4]  E. Topol,et al.  Administration of Recombinant P-Selectin Glycoprotein Ligand Fc Fusion Protein Suppresses Inflammation and Neointimal Formation in Zucker Diabetic Rat Model , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[5]  A. Weyrich,et al.  Platelets, endothelial cells, inflammatory chemokines, and restenosis: complex signaling in the vascular play book. , 2002, Circulation.

[6]  K. Ley,et al.  Deposition of Platelet RANTES Triggering Monocyte Recruitment Requires P-Selectin and Is Involved in Neointima Formation After Arterial Injury , 2002, Circulation.

[7]  E. Topol,et al.  Death Following Creatine Kinase-MB Elevation After Coronary Intervention: Identification of an Early Risk Period: Importance of Creatine Kinase-MB Level, Completeness of Revascularization, Ventricular Function, and Probable Benefit of Statin Therapy , 2002, Circulation.

[8]  A. Zeiher,et al.  CD40 Ligand Inhibits Endothelial Cell Migration by Increasing Production of Endothelial Reactive Oxygen Species , 2002, Circulation.

[9]  Deepak L. Bhatt,et al.  Need to test the arterial inflammation hypothesis. , 2002, Circulation.

[10]  S. Harder,et al.  Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P‐selectin expression in a human ex vivo in vitro model , 2002, Clinical pharmacology and therapeutics.

[11]  R. Hynes,et al.  CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism , 2002, Nature Medicine.

[12]  S. Sdringola,et al.  Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). , 2001, The American journal of cardiology.

[13]  Deepak L. Bhatt,et al.  Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. , 2001, The American journal of cardiology.

[14]  F. Picard,et al.  Flow Cytometry Detection of Platelet Procoagulant Activity and Microparticles in Patients with Unstable Angina Treated by Percutaneous Coronary Angioplasty and Stent Implantation , 2001, Thrombosis and Haemostasis.

[15]  Deepak L. Bhatt,et al.  Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention , 2001, Circulation.

[16]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[17]  R. Kroczek,et al.  The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. , 2001, Blood.

[18]  S. Aksöyek,et al.  Platelet and Leukocyte Deactivation After Intracoronary Stent Placement in Patients Receiving Combined Antiplatelet Therapy , 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[19]  P. Crean,et al.  Relationship between intracoronary and peripheral expression of soluble cell adhesion molecules. , 2001, International journal of cardiology.

[20]  K. Schrör,et al.  Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel , 2001, Platelets.

[21]  U. Ikeda,et al.  Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis , 2000, Heart.

[22]  M. Daemen,et al.  Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Libby,et al.  Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. McIntire,et al.  Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. , 2000, Circulation.

[25]  M. Daemen,et al.  Requirement for CD154 in the progression of atherosclerosis , 1999, Nature Medicine.

[26]  K. Forfang,et al.  Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. , 1999, Circulation.

[27]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[28]  F. Gries,et al.  Platelet Membrane Activation Markers Are Predictive for Increased Risk of Acute Ischemic Events After PTCA , 1993, Circulation.